Results 161 to 170 of about 1,419,720 (263)

How developmental stressors affect mitochondrial respiratory function: a systematic review and meta‐analysis

Biological Reviews, Volume 101, Issue 6, Page 2756-2779, December 2026.
ABSTRACT The environmental conditions organisms experience during early development can have powerful and sustained effects on morphology, physiology, behaviour, and performance. Such developmental effects can influence reproductive success, survival, and life‐history strategies and can be transmitted across generations (i.e.
Ondi L. Crino, Christopher R. Friesen, Geoffrey E. Hill, Dalton C. Leibold, Pablo Recio, Karine Salin, Kristoffer H. Wild, Daniel W.A. Noble   +7 more
wiley   +1 more source

Mineralocorticoid receptor antagonists and mortality in hypertension: a systematic review and meta-analysis. [PDF]

J Hypertens
Teh JW, Comerford G, Surlis G, Curneen J, Krewer F, Smyth A, Lappin D, Mcevoy JW, Dennedy MC, Judge C.   +9 more
europepmc   +1 more source

Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates

Diabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 10931-10949, December 2026.
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou, Christoforos K. Travlos, Lucas Lage Marinho, Thomas A. Mavrakanas, João Pedro Ferreira, Abhinav Sharma   +5 more
wiley   +1 more source

A comparative real-world analysis of finerenone and steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease. [PDF]

Front Pharmacol
Vetrano D, Cianciolo G, Barbuto S, Ribichini D, Berti S, Mistretta A, Ginesi M, Millar PT, Grimaldi A, Vischini G, Poluzzi E, Pagotto U, La Manna G, Capelli I.   +13 more
europepmc   +1 more source

The SGLT2i Treatment Gap in UK Primary Care: A Cross‐Sectional RWE Study of Prescribing in Clinical Practice

Diabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11278-11287, December 2026.
ABSTRACT Aims Sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) improve cardiovascular and renal outcomes in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD) and chronic heart failure (CHF). Despite clinical guideline recommendations, SGLT2i uptake in UK primary care remains suboptimal and information on utilisation is limited.
Chelsea Stefanska, Ryan Chung, Salman Ramjaun, Danyao Jin, Ciara Doherty, Kieran McCafferty, Samuel Seidu   +6 more
wiley   +1 more source

Steroidal versus Nonsteroidal Mineralocorticoid Receptor Antagonists in CKD. [PDF]

J Am Soc Nephrol
Khan MS, Rashid AM, Flythe JE, Dember LM, Shafi T.   +4 more
europepmc   +1 more source

Effects of Renin–Angiotensin Inhibitors, Sodium–Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon‐Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11320-11327, December 2026.
ABSTRACT Aims While the new kidney protective therapies have transformed chronic kidney disease (CKD) management in patients with Type 2 diabetes mellitus (T2DM), treatment options for CKD in Type 1 diabetes mellitus (T1DM) have remained unchanged for 30 years, limited to renin–angiotensin system inhibitors (RASis).
Frances Perry, Silvia J. Leon, Kate Polecina, Ruth Getachew, Nicole Askin, Thomas Ferguson, Reid Whitlock, Zihe Zheng, Carolina Aldworth, Arvind Katta, Jacob Earl, Mauricio Beller Ferri, Navdeep Tangri   +12 more
wiley   +1 more source

Mechanisms for Mineralocorticoid-Driven Age-Related Hypertension: Potential Therapeutic Role of Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors. [PDF]

Circ Res
Golec S, Vaidya A, Pitt B, Jaffe IZ.
europepmc   +1 more source

Histopathological stratification of primary aldosteronism using the CYP11B2 size ratio: first evaluation in clinical routine

Histopathology, Volume 89, Issue 6, Page 1011-1019, December 2026.
CYP11B2 immunohistochemistry identifies aldosterone‐producing nodules and enables objective subtyping using the B2 ratio (B2R), defined as the size ratio between the largest and second‐largest CYP11B2‐positive nodules. A B2R ≥8.1 indicates classical histology with a dominant lesion and high likelihood of cure, whereas B2R <8.1 reflects non‐classical ...
Adam Stenman, Tim Nilsson, Henrik Falhammar, C. Christofer Juhlin   +3 more
wiley   +1 more source

Mineralocorticoid Receptor Antagonists and Acute Heart Failure [PDF]

European Journal of Heart Failure, 2019
Carlos, Escobar, Luis, Manzano
openaire   +2 more sources